Membership Home Portfolio Stocks Bonds Funds ETFs CEFs Markets Tools Real Life Finance Discuss

Articles From: Rentrak Announces Worldwide Box Office Results For Weekend Of June 2, 2013 to Swiss Banks Have 120 Days To Settle U.S. Tax Deal-Report

This site contains about 74,006 documents.
View by:
Title  |  Date  |  Author  |  Collection  |  Interest  |  Popularity
Page:   1   1,400   1,500   1,600   1,700   1,800   1,900   2,000   2,100   2,200   2,300   2,310   2,320   2,330   2,340   2,350   2,360   2,370   2,380   2,385   2,386   2,387   2,388   2,389   2,390   2,391   2,392   2,393   2,394   2,395   2,396   2,397   2,398   2,399   2,400   2,401   2,402   2,403   2,404   2,405   2,406   2,407   2,408   2,409   2,410   2,411   2,412   2,413   2,414   2,420   2,430   2,440   2,450   2,460   2,467 

2013/6/2
Rentrak Announces Worldwide Box Office Results For Weekend Of June 2, 2013
--Only Rentrak Provides the Global Standard in Box Office Reporting--
View more Rentrak Announces Worldwide Box Office Results For Weekend Of June 2, 2013 analysis
Sign-up for Rentrak Announces Worldwide Box Office Results For Weekend Of June 2, 2013 investment picks
2013/6/2
Correction to Stories on Thyroid Cancer Drug From Bayer, Onyx
The story "Thyroid Cancer Drug From Bayer, Onyx Helps Halt Disease's Progress," published at 7:30 a.m. EDT and " UPDATE: Thyroid Cancer Drug From Bayer, Onyx Helps Halt Disease's Progress," at 12:58 p.m. EDT , incorrectly referred to Tony Coles, Onyx Pharmaceuticals Inc. chairman and chief executive, as Mr.
View more Correction to Stories on Thyroid Cancer Drug From Bayer, Onyx analysis
Sign-up for Correction to Stories on Thyroid Cancer Drug From Bayer, Onyx investment picks
2013/6/2
UPDATE: Merck Drug Shrinks Tumors in Melanoma Patients in Study
--Merck's experimental lambrolizumab shrinks tumors in 38% of melanoma patients in study --Merck to study drug in late-stage trials in melanoma and lung cancer --Similar drug from Bristol-Myers also shows promise in studies (Adds updated data for Bristol-Myers' drug in 10th paragraph.) By Peter Loftus CHICAGO --An experimental Merck & Co.
View more UPDATE: Merck Drug Shrinks Tumors in Melanoma Patients in Study analysis
Sign-up for UPDATE: Merck Drug Shrinks Tumors in Melanoma Patients in Study investment picks
2013/6/2
First Boeing 787-9 Dreamliner Begins Final Assembly
Newest 787 complements, extends the super-efficient family EVERETT, Wash.
View more First Boeing 787-9 Dreamliner Begins Final Assembly analysis
Sign-up for First Boeing 787-9 Dreamliner Begins Final Assembly investment picks
2013/6/2
PULSE: China developer buys stake in GM Building: report
WASHINGTON (MarketWatch) - A group including a prominent Chinese developer has purchased a 40% stake in the General Motors Building in midtown Manhattan, according to a report by Dow Jones Newswires.
View more PULSE: China developer buys stake in GM Building: report analysis
Sign-up for PULSE: China developer buys stake in GM Building: report investment picks
2013/6/2
Total CEO Sees More European Refineries Closing in Coming Years
PARIS --More European refineries, including some in France , are likely to shut down in the coming years, as refined-oil products consumption is falling in the region, Total SA (TOT, FP.FR) Chairman and Chief Executive Christophe de Margerie said Sunday.
View more Total CEO Sees More European Refineries Closing in Coming Years analysis
Sign-up for Total CEO Sees More European Refineries Closing in Coming Years investment picks
2013/6/2
Advaxis Reports Survival and New Analysis for ADXS-HPV in Patients with Recurrent Cervical Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Advaxis, Inc ., (OTCBB: ADXS) , a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced today final 12 month overall survival and additional data from Lm -LLO-E7-15, a randomized Phase 2 study evaluating the safety and efficacy of ADXS-HPV +/- cisplatin in patients with recurrent cervical cancer.
View more Advaxis Reports Survival and New Analysis for ADXS-HPV in Patients with Recurrent Cervical Cancer at the 2013 American Society of Clinical Oncology Annual Meeting analysis
Sign-up for Advaxis Reports Survival and New Analysis for ADXS-HPV in Patients with Recurrent Cervical Cancer at the 2013 American Society of Clinical Oncology Annual Meeting investment picks
2013/6/2
Canadian Pacific Container Train Derails in Northern Ontario
TORONTO --A container train operated by Canadian Pacific Ltd.
View more Canadian Pacific Container Train Derails in Northern Ontario analysis
Sign-up for Canadian Pacific Container Train Derails in Northern Ontario investment picks
2013/6/2
UPDATE: Thyroid Cancer Drug From Bayer, Onyx Helps Halt Disease's Progress
Bayer AG (BAYN.XE, BAYRY) and Onyx Pharmaceuticals Inc. (ONXX) said their drug Nexavar helped to nearly double the number of months that patients with a rare type of advanced thyroid cancer lived without their diseases worsening--but that the drug made no difference in patients' overall survival.
View more UPDATE: Thyroid Cancer Drug From Bayer, Onyx Helps Halt Disease's Progress analysis
Sign-up for UPDATE: Thyroid Cancer Drug From Bayer, Onyx Helps Halt Disease's Progress investment picks
2013/6/2
Bristol-Myers Squibb Announces Phase 1 Results from First Trial Combining Immune Checkpoint Inhibitors, Investigational Agent Nivolumab and Yervoy® (ipilimumab), in Patients with Advanced Melanoma
Bristol-Myers Squibb Company (NYSE: BMY) today announced results from Study 004, a dose-ranging Phase 1 trial (n=86) evaluating the safety and anti-tumor activity of its investigational PD-1 receptor blocker, nivolumab, combined either concurrently (n=53) or sequentially (n=33) with Yervoy ® (ipilimumab) in patients with advanced melanoma.
View more Bristol-Myers Squibb Announces Phase 1 Results from First Trial Combining Immune Checkpoint Inhibitors, Investigational Agent Nivolumab and Yervoy® (ipilimumab), in Patients with Advanced Melanoma analysis
Sign-up for Bristol-Myers Squibb Announces Phase 1 Results from First Trial Combining Immune Checkpoint Inhibitors, Investigational Agent Nivolumab and Yervoy® (ipilimumab), in Patients with Advanced Melanoma investment picks
2013/6/2
Merck Drug Shrinks Tumors in Melanoma Patients in Study
CHICAGO --An experimental Merck & Co.
View more Merck Drug Shrinks Tumors in Melanoma Patients in Study analysis
Sign-up for Merck Drug Shrinks Tumors in Melanoma Patients in Study investment picks
2013/6/2
Merck Announces Presentation of Interim Data from Study Evaluating Lambrolizumab, an Investigational Anti-PD-1 Antibody, in Patients with Advanced Melanoma at ASCO 2013
Merck (NYSE: MRK) , known as MSD outside the United States and Canada, today announced the presentation of preliminary results from an ongoing Phase IB expansion study evaluating the safety and efficacy of lambrolizumab (MK-3475), Merck’s investigational antibody therapy targeting PD-1, in patients with advanced (inoperable and metastatic) melanoma.
View more Merck Announces Presentation of Interim Data from Study Evaluating Lambrolizumab, an Investigational Anti-PD-1 Antibody, in Patients with Advanced Melanoma at ASCO 2013 analysis
Sign-up for Merck Announces Presentation of Interim Data from Study Evaluating Lambrolizumab, an Investigational Anti-PD-1 Antibody, in Patients with Advanced Melanoma at ASCO 2013 investment picks
2013/6/2
Agilent Technologies to Exhibit at IMS2013 International Microwave Symposium, booth 1230, Jun 2 - 7, 2013, in Seattle, WA, US
Press Kit Materials are Available at: http://www.tradeshownews.com/events/IMS2013-International-Microwave-Symposium/Agilent/ About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications.
View more Agilent Technologies to Exhibit at IMS2013 International Microwave Symposium, booth 1230, Jun 2 - 7, 2013, in Seattle, WA, US analysis
Sign-up for Agilent Technologies to Exhibit at IMS2013 International Microwave Symposium, booth 1230, Jun 2 - 7, 2013, in Seattle, WA, US investment picks
2013/6/2
Guidewire Software Announces Data Management and Business Intelligence Products
Guidewire Software, Inc. (NYSE: GWRE) , a provider of software products to Property/Casualty (P/C) insurers, today announced its new data management and business intelligence solutions, Guidewire DataHub™ and Guidewire InfoCenter™ based on technology acquired from Millbrook 1 .
View more Guidewire Software Announces Data Management and Business Intelligence Products analysis
Sign-up for Guidewire Software Announces Data Management and Business Intelligence Products investment picks
2013/6/2
Monsanto Won't Apply For New Genetically Modified Seeds In Europe
Monsanto doesn't plan to apply for the approval of new genetically modified seeds in Europe due to low demand from farmers and stiff opposition from the general public, the U.S. agricultural company's German spokeswoman said Sunday.
View more Monsanto Won't Apply For New Genetically Modified Seeds In Europe analysis
Sign-up for Monsanto Won't Apply For New Genetically Modified Seeds In Europe investment picks
2013/6/2
Western Potash Corp. Receives Strategic Investment from China BlueChemical Ltd. and GUOXIN International Investment Corporation Limited.
Western Potash Corp (“Western” or the “Company”) (TSX: WPX) today announced that China BlueChemical Ltd.
View more Western Potash Corp. Receives Strategic Investment from China BlueChemical Ltd. and GUOXIN International Investment Corporation Limited. analysis
Sign-up for Western Potash Corp. Receives Strategic Investment from China BlueChemical Ltd. and GUOXIN International Investment Corporation Limited. investment picks
2013/6/2
In a Major Milestone, Ad Astra & Cummins Inc. Successfully Use Hydrogen/Biogas to Power a Cummins Generator in Costa Rica
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G005499-001&sourceType=1 http://www.marketwire.com/library/MwGo/2013/6/2/11G005499/Clipboard02-927103781526.jpg http://www.marketwire.com/library/MwGo/2013/6/2/11G005499/Clipboard01-228516190275.jpg LIBERIA, COSTA RICA --(Marketwired - June 02, 2013) -  In a significant scientific and environmental achievement, a combined team of engineers and technicians from Ad Astra Rocket Company and Cummins Power Generation, a business unit of global power leader Cummins Inc., (NYSE: CMI) have successfully powered a Cummins-built electrical generator using mixtures of hydrogen and biogas.
View more In a Major Milestone, Ad Astra & Cummins Inc. Successfully Use Hydrogen/Biogas to Power a Cummins Generator in Costa Rica analysis
Sign-up for In a Major Milestone, Ad Astra & Cummins Inc. Successfully Use Hydrogen/Biogas to Power a Cummins Generator in Costa Rica investment picks
2013/6/2
Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate (ADC) Collaborator Data at ASCO Annual Meeting
Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted ongoing clinical development programs for ADCETRIS (brentuximab vedotin) in frontline Hodgkin lymphoma (HL) and mature T-cell lymphoma (MTCL) and progress with collaborator antibody-drug conjugate (ADC) programs that were presented at the 49 th Annual Meeting of the American Society of Clinical Oncology being held May 31 – June 4, 2013, in Chicago, IL.
View more Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate (ADC) Collaborator Data at ASCO Annual Meeting analysis
Sign-up for Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate (ADC) Collaborator Data at ASCO Annual Meeting investment picks
2013/6/2
Exelixis Presents COMETRIQ™ (cabozantinib) Clinical Trial Data in Patients with Progressive, Metastatic Medullary Thyroid Cancer
Exelixis, Inc. (NASDAQ:EXEL) today announced the presentation of additional data from clinical trials of COMETRIQ™ (cabozantinib) in patients with progressive, metastatic medullary thyroid cancer (MTC). The data were presented this weekend at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO). Long-term follow-up of a phase 1 trial (Abstract #6090) shows that 30% of progressive, metastatic MTC patients treated with COMETRIQ experienced disease control (DC) and have remained progression-free for more than 2 years.
View more Exelixis Presents COMETRIQ™ (cabozantinib) Clinical Trial Data in Patients with Progressive, Metastatic Medullary Thyroid Cancer analysis
Sign-up for Exelixis Presents COMETRIQ™ (cabozantinib) Clinical Trial Data in Patients with Progressive, Metastatic Medullary Thyroid Cancer investment picks
2013/6/2
ARIAD Announces Long-Term Durability-of-Response Data on Ponatinib from Ongoing Phase 1 Study
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced long-term durability-of-response data from its Phase 1 trial of Iclusig ® (ponatinib) in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study shows that among chronic-phase (CP) patients, the median durations of major and complete cytogenetic responses, along with major molecular response, have yet to be reached.
View more ARIAD Announces Long-Term Durability-of-Response Data on Ponatinib from Ongoing Phase 1 Study analysis
Sign-up for ARIAD Announces Long-Term Durability-of-Response Data on Ponatinib from Ongoing Phase 1 Study investment picks
2013/6/2
ARIAD Presents Updated Phase 1 Data on AP26113 in Patients with Non-Small Cell Lung Cancer
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113 , in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial.
View more ARIAD Presents Updated Phase 1 Data on AP26113 in Patients with Non-Small Cell Lung Cancer analysis
Sign-up for ARIAD Presents Updated Phase 1 Data on AP26113 in Patients with Non-Small Cell Lung Cancer investment picks
2013/6/2
Threshold Pharmaceuticals Announces Data From Two Ongoing Phase 1/2 Trials of TH-302 at the 2013 ASCO Annual Meeting
http://media.marketwire.com/attachments/201211/99925_41732_threshold.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1022734&ProfileId=051205&sourceType=1 SOUTH SAN FRANCISCO, CA --
View more Threshold Pharmaceuticals Announces Data From Two Ongoing Phase 1/2 Trials of TH-302 at the 2013 ASCO Annual Meeting analysis
Sign-up for Threshold Pharmaceuticals Announces Data From Two Ongoing Phase 1/2 Trials of TH-302 at the 2013 ASCO Annual Meeting investment picks
2013/6/2
Infinity Reports Updated Phase 1 Data Showing Encouraging Clinical Activity of IPI-145 in Chronic Lymphocytic Leukemia at ASCO Annual Meeting
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced updated Phase 1 data from an ongoing study of IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), a potentially fatal hematologic malignancy, or blood cancer.
View more Infinity Reports Updated Phase 1 Data Showing Encouraging Clinical Activity of IPI-145 in Chronic Lymphocytic Leukemia at ASCO Annual Meeting analysis
Sign-up for Infinity Reports Updated Phase 1 Data Showing Encouraging Clinical Activity of IPI-145 in Chronic Lymphocytic Leukemia at ASCO Annual Meeting investment picks
2013/6/2
ENRC Founders To Extend Deadline For Takeover Offer-Report
LONDON --The founding shareholders of Eurasian Natural Resources Corp.
View more ENRC Founders To Extend Deadline For Takeover Offer-Report analysis
Sign-up for ENRC Founders To Extend Deadline For Takeover Offer-Report investment picks
2013/6/2
Driving Quality in a Fast-Paced Agile Environment Presented by IBM and SmartBear at IBM Innovate 2013
Mark Hammer , Senior Product Director at SmartBear Software , provider of software quality tools used by more than one million developers and testers worldwide, is speaking on the panel, “Experiences Driving Quality in a Fast-Paced Agile Environment through Integrated Product Lifecycle Artifact Review,” at IBM Innovate 2013 on Wednesday, June 5, 2013 in Orlando, Florida.
View more Driving Quality in a Fast-Paced Agile Environment Presented by IBM and SmartBear at IBM Innovate 2013 analysis
Sign-up for Driving Quality in a Fast-Paced Agile Environment Presented by IBM and SmartBear at IBM Innovate 2013 investment picks
2013/6/2
Thyroid Cancer Drug From Bayer, Onyx Helps Halt Disease's Progress
Bayer AG (BAYN.XE, BAYRY) and Onyx Pharmaceuticals Inc. (ONXX) said their drug Nexavar helped to nearly double the number of months that patients with a rare type of advanced thyroid cancer lived without their diseases worsening--but that the drug made no difference in patients' overall survival.
View more Thyroid Cancer Drug From Bayer, Onyx Helps Halt Disease's Progress analysis
Sign-up for Thyroid Cancer Drug From Bayer, Onyx Helps Halt Disease's Progress investment picks
2013/6/2
Phase 3 DECISION Trial Investigating the Use of Nexavar® (sorafenib) Demonstrated Significant Improvement in Progression-Free Survival in Patients with Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Data to be Presented at Plenary Session at Annual Meeting of the American Society of Clinical Oncology Data Form Basis for Regulatory Submission Mid-Year in the United States; Additional Submissions to Follow Globally WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif.
View more Phase 3 DECISION Trial Investigating the Use of Nexavar® (sorafenib) Demonstrated Significant Improvement in Progression-Free Survival in Patients with Radioactive Iodine-Refractory Differentiated Thyroid Cancer analysis
Sign-up for Phase 3 DECISION Trial Investigating the Use of Nexavar® (sorafenib) Demonstrated Significant Improvement in Progression-Free Survival in Patients with Radioactive Iodine-Refractory Differentiated Thyroid Cancer investment picks
2013/6/2
Almunia Says EU Will Open Up Pharma Markets in Europe-Report
The European Commission will do more to open up pharmaceutical markets in Europe for cheaper generic alternatives to drugs, European Commissioner for Competition Joaquin Almunia told German weekly Focus magazine .
View more Almunia Says EU Will Open Up Pharma Markets in Europe-Report analysis
Sign-up for Almunia Says EU Will Open Up Pharma Markets in Europe-Report investment picks
2013/6/2
SNB's Jordan: Central Bank Not Mandated to Rescue Banks -Report
The Swiss National Bank is responsible for maintaining the stability of the country's financial system but isn't obligated to rescue banks, central bank President Thomas Jordan said in an interview with Schweiz am Sonntag on Sunday.
View more SNB's Jordan: Central Bank Not Mandated to Rescue Banks -Report analysis
Sign-up for SNB's Jordan: Central Bank Not Mandated to Rescue Banks -Report investment picks
2013/6/2
Swiss Banks Have 120 Days To Settle U.S. Tax Deal-Report
ZURICH --Swiss banks trying to settle legacy tax evasion issues with the U.S. will only have 120 days in which to reach an agreement with the U.S. Department of Justice , NZZ am Sonntag reports Sunday, citing sources in the financial sector.
View more Swiss Banks Have 120 Days To Settle U.S. Tax Deal-Report analysis
Sign-up for Swiss Banks Have 120 Days To Settle U.S. Tax Deal-Report investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Site Directory Site Map Our Products
Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
Articles From: Rentrak Announces Worldwide Box Office Results For Weekend Of June 2, 2013 to Swiss Banks Have 120 Days To Settle U.S. Tax Deal-Report
Stocks by:
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry
Mutual Funds by:
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title
ETFs by:
Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name
Investment Categories by:
Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry
Premimum Stocks by:
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry
Premimum Funds by:
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title
Premimum ETFs by:
Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name
Popular Articles by:
Title |  Date |  Author |  Collection |  Popularity |  Interest
SEC Filings by:
Title |  Date |  Company |  Symbol |  Interest |  Popularity
Popular SEC Filings by:
Title |  Date |  Company |  Symbol |  Interest |  Popularity
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.